cytori therapeutics

March 30, 2016April 4, 2016

Cytori Updates Phase 3 Scleroderma Trial After Enrolling, Treating 40th Patient

News, Scleroderma

Cytori Therapeutics recently announced that its FDA-approved Phase 3 STAR clinical trial on ECCS-50 has enrolled and treated its 40th patient, reaching 50 percent of its target enrollment. Additionally, an independent ... Read more

September 15, 2015November 6, 2015

Cytori Therapeutics’ Scleroderma Therapy Shows Promising Results After 12 Months of Treatment

News, Scleroderma

Cytori Therapeutics a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently announced the results from a 12-month follow-up of patients ... Read more

December 22, 2014November 6, 2015

Cytori To Host Informational Session On Scleroderma, STAR Pivotal Trial

News, Scleroderma

On January 14, 2015, Cytori Therapeutics, Inc. will host an information session about advances in scleroderma research and the company’s STAR pivotal trial for its own experimental Scleroderma therapy. This session will take ... Read more

December 11, 2014November 6, 2015

‘STAR’ Trial In Scleroderma By Cytori Therapeutics Receives FDA Conditional Approval

News, Scleroderma

Cytori Therapeutics, Inc. received a conditional investigational device exemption (IDE) approval from the Food and Drug Administration (FDA) to launch the STAR trial in order to evaluate Cytori Cell Therapy as a ... Read more